Sturge-Weber Syndrome

Welcome to PT 635 Pathophysiology of Complex Patient Problems This is a wiki created by and for the students in the School of Physical Therapy at Bellarmine University in Louisville KY. Please do not edit unless you are involved in this project, but please come back in the near future to check out new information!!

Original Editors - Marti Bradbury & Kayla Stull from Bellarmine University's Pathophysiology of Complex Patient Problems project.

Lead Editors - Your name will be added here if you are a lead editor on this page.  Read more.

Definition/Description[edit | edit source]

add text here

Prevalence[edit | edit source]

add text here

Characteristics/Clinical Presentation[edit | edit source]

add text here

Associated Co-morbidities[edit | edit source]

add text here

Medications4[edit | edit source]

Medications used to treat Sturge-Weber Disease will vary greatly depending the presentation of symptoms in those with the disorder. Medical Intervention can include any of the following:

  • Anticonvulsants work to discontinue electrical siezure activity quickly and reduce the likelihood of siezure reoccurance. Examples of these medications include Carbamazepine (Tegretol), Phenytoin (Dilantin), Valproic acid (Depakote, Depakene, Depacon), Gabapentin (Neurontin), Lamotrigine (Lamictal), as well as many others.


  • Beta Blockers are used to help decrease intraoccular pressure by reducing the amount of aqueous humor produced in the eye. Aqueous humor is a plasma-like substance largely composed of protiens which help support and nourish occular tissue. Aqueous humor also assists in maintaining appropriate intraoccular pressure but in those with Sterge-Weber Syndrome this substance is overproduced. Levobunolol 0.25% or 0.5% (Betagan) is a beta blocker commonly used in Sterge-Weber Disease.


  • Carbonic Anhydrase Inhibitors lower intraoccular pressure in much the same way that beta blockers do, by reducing production of aqueous humor. These drugs include Dorzolamide 2% (Trusopt) and Brinzolamide 1% (Azopt).


  • Prostaglandin Analogues also work to lower intraoccular pressure, though instead of decreasing aqueous production directly they, instead, increase the outflow of the fluid away from the eye through the proper pathway. This pathway is known as the uveoscleral pathway and is located inferior to the eye. Latanoprost 0.005% (Xalatan) is a prostaglandin analogue used for this purpose.


  • Topical Corticosteroids are used to treat occular. Prednisolone acetate 1% inhibits the edema, fibrin deposition,capillary dilation and phagocytic migration during the acute inflammatory response.  Dexamethasone ophthalmic (Maxidex, Ozurdex) and Triamcinolone (Triesence) work by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability.


  • Antineoplastic Agents work by inhibiting DNA synthesis in order to decrease or stop cell growth and proliferation. Two examples of antineoplastic agents are Fluorouracil (Efudex) and Mitomycin.

Diagnostic Tests/Lab Tests/Lab Values[edit | edit source]

add text here

Etiology/Causes[edit | edit source]

add text here

Systemic Involvement[edit | edit source]

add text here

Medical Management (current best evidence)[edit | edit source]

add text here

Physical Therapy Management (current best evidence)[edit | edit source]

add text here

Alternative/Holistic Management (current best evidence)[edit | edit source]

add text here

Differential Diagnosis[edit | edit source]

add text here

Case Reports/ Case Studies[edit | edit source]

add links to case studies here (case studies should be added on new pages using the case study template)

Resources
[edit | edit source]

add appropriate resources here

Recent Related Research (from Pubmed)[edit | edit source]

see tutorial on Adding PubMed Feed

Failed to load RSS feed from http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1NGmwZeh8JwVIzrKgHG1LrDm0izTr7ViJiDkSYAY2BW5hiXsx0|charset=UTF-8|short|max=10: Error parsing XML for RSS

References[edit | edit source]

see adding references tutorial.

3. Pascual-Castroviejo I, Pascual-Pascual S, Velazquez-Fragua R, Viaño J. Sterge-Weber Syndrome. Study of 55 patients. J of Can Neuro Sciences. 2008. 35(3); 301-307.